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The experience, satisfaction, and Emergency Department utilization of
pediatric patients with sickle cell disease during the Covid-19 pandemic
Alexandra E. Kirsch, St. Christopher's Hospital for Children, alexandra.kirsch@towerhealth.org
Nataly Apollonsky, St. Christopher's Hospital for Children, nataly.apollonsky@towerhealth.org
Abstract
The COVID-19 pandemic has influenced how patients utilize healthcare. This study examines the utilization, experience,
and satisfaction of patients with Sickle Cell Disease (SCD) in the pediatric Emergency Department (ED) during the
COVID-19 pandemic compared to the care they had received before the pandemic. The authors surveyed fifty-eight
participants ages 14 months to 20 years who presented to the ED for a complaint related to their SCD during the
COVID-19 pandemic. The study analyzed five variables: race, SCD severity, hemoglobin (Hgb) genotype, who
completed the questionnaire (patient versus parent/guardian), and whether the ED visit resulted in an admission to the
hospital. Our results suggest that the COVID-19 pandemic significantly affected the decision of some patients as to
whether and when to go to the ED. African Americans and those with severe disease did not wait longer than usual to
go to the ED, possibly because these groups are more likely to have more serious and more frequent pain crises. Thus,
their decision to present to the ED was driven more by their relatively worse symptoms, rather than such external
factors as the pandemic. However, the pandemic did not significantly affect patients’ satisfaction with their ED visit or
their baseline SCD symptoms. To our knowledge, this is the first study of how the COVID-19 pandemic has affected
patients’ utilization of, experience in, and satisfaction with a pediatric hospital ED.
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Introduction
There are approximately 100,000 people in the United
States afflicted with the group of inherited
hemoglobinopathies known collectively as sickle cell
disease (SCD).1 The vast majority of patients with SCD are
of African or Hispanic descent. Nationally, patients with
SCD account for approximately 200,000 Emergency
Department (ED) visits annually.2 Patients with SCD may
suffer from numerous complications including chronic
pain, progressive multi-system organ damage, retinopathy,
embolism and stroke, acute chest syndrome, and increased
susceptibility to life-threatening infections, especially in the
pediatric population.2-3 Acute pain exacerbation due to a
vaso-occlusive crisis is the most common reason for
patients with SCD to visit the ED and often requires
treatment with parenteral opioid medication.2-4
Patients with SCD who contract SARS-CoV-2 have a
higher risk of complications, severe disease course, and
death compared to the general population.5 In a study of
178 patients with SCD and COVD-19 infection reported
to the SECURE-SCD registry between March and May
2020, Panepinto and colleagues found that 90% of patients
accessed care through an ED, 69% required

hospitalization, 11% were admitted to an intensive care
unit, and 7% died.5 Thus, patients with SCD who delay or
avoid seeking emergency medical care due to the COVID19 pandemic may be at an increased risk of adverse
outcomes.
The National Syndromic Surveillance Program found that
ED visits decreased 42% overall during the early stages of
the COVID-19 pandemic.6 Patients with SCD have
consistently expressed a significant level of dissatisfaction
regarding the ED care they have received, especially when
compared to the care that these patients have received
from their usual physician.7-8 The multifactorial reasons
that patients with SCD are dissatisfied with ED care
include, but are not limited to, long wait times that may
result in treatment delays, lack of communication and comanagement between the ED and patients’ primary
medical provider, perceived lack of empathy, absence of
standardized treatment protocols, ED provider attitudes
and discomfort with acute pain management in this patient
population, and inadequate analgesic dosing.7-8 The wellestablished negative perception of ED care raised the
question of the COVID-19 pandemic’s impact on the
decision-making process of patients with SCD. This study
examines whether and when patients with SCD sought
ED care and their satisfaction with and experience in the
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ED during the COVID-19 pandemic compared to the ED
care that they received before the pandemic.
Very few studies have focused on pediatric patients with
sickle cell disease and healthcare utilization during the
COVID-19 pandemic. Tsitsikas and colleagues evaluated
the strategy of preventing hospitalizations and extended
hospitalizations in the United Kingdom.9 One study
surveyed providers at 28 practices to determine how the
COVID-19 pandemic affected outpatient care of patients
with SCD.10 Another study assessed the level of anxiety of
adolescents and young adults with SCD to evaluate the
correlation between COVID-19 experiences, anxiety
levels, and painful episodes.11 Finally, one study evaluated
how the pandemic and stay-at-home orders affected ED
visits to a tertiary care hospital; although this study
reviewed all patients presenting to the ED, there was a
small subset who had sickle cell disease.12 To our
knowledge, this is the first study to investigate the effect of
the COVID-19 pandemic on the utilization of, experience
in, and satisfaction with Emergency Department services
by pediatric patients with sickle cell disease.

Materials and Methods
Participants

Potential study participants were identified from patients
with a diagnosis of SCD who were followed long-term at

the Marian Anderson Sickle Cell Center at St.
Christopher’s Hospital for Children. The center maintains
a database of its patients; the authors mined the database
to identify patients with SCD who visited the ED for a
complaint related to their SCD during the COVID-19
pandemic (February 2020 – March 2021). Potential
participants were contacted to verify the information,
ensure that they met the inclusion criteria, and were willing
to participate in the study.
A total of 58 participants were included in the study. Of
these, 23 (40%) were female and 35 (60%) were male. The
ages ranged from 14 months to 20 years (m = 13.8 years,
SD = 5.98 years).
Most of the patients had sickle cell SS (n = 27; 47%),
followed by SC (n = 20; 35%), S+ thalassemia, (n = 7,
12%), S0 thalassemia (n = 2; 3%) and S/HPFH (n = 2;
3%). The disease was classified as severe if patients had
more than three hospital admissions in a year, cerebral
vasculopathy, chronic packed red blood cell transfusions,
or a history of acute chest syndrome in the last three years.
Most patients were classified as not severe (n = 40; 69%)
rather than severe (n = 18; 31%). Most of the participants
were African American (n = 48; 83%) followed by
Hispanic (n = 6; 10%) and those who self-identified as
“other” (n = 4; 7%). Table 1 summarizes the
demographics of the participants.

Table 1. Patient Demographics

Gendera

Variable

n (%) or mean (SD)

Female

23 (40%)

Male

35 (60%)

Age in years
Hgb Genotype

Disease Severity
Raceb

13.8 (5.98)
SS

27 ( 47%)

SC

20 (35%)

S+ thalassemia

7 (12%)

S0 thalassemia

2 (3%)

S/HPFH

2 (3%)

Severe

18 (31%)

Not Severe

40 (69%)

African American
Hispanic

48 (83%)
6 (10%)

Other

4 (7%)

aGender
bRace
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as identified from the electronic medical record.
was self-identified by the patient and/or parent/guardian
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Table 2. Likert Questionnaire Responses Scored from
Strongly Disagree (1) to Strongly Agree (5)
1) My decision to go to the Emergency Room was
affected by the COVID pandemic.
2) I waited longer before going to the Emergency
Room (vs. before the pandemic).
3) I tried more medications at home for fever and/or
pain (vs. before the pandemic).
4) My experience in the Emergency Room was better
during the pandemic (vs. before the pandemic).
5) I got to a room and/or got care faster during the
pandemic (vs. before the pandemic).
6) I felt the hospital took the proper COVID-related
precautions (e.g., staff wore masks, ER was cleaned
regularly, etc.).
7) I feel like my Sickle Cell Disease symptoms (pain,
fever, etc.) are milder now (vs. before the pandemic).

Intervention

Patient responses to their experience in and satisfaction
with a recent Emergency Department visit were recorded
using a specifically-designed Likert questionnaire (Table 2).
Telephone interviews were conducted in lieu of in-person
interviews due to social distancing and safety measures
implemented during the COVID-19 pandemic. The
responses to these seven questions were graded on a 1 to 5
Likert scale, with 1 signifying strong disagreement and 5
signifying strong agreement (Table 2). Analysis of
covariance was performed to compare means. The
remaining four questions, numbered 8 through 12, were
open-ended or yes/no questions (Table 3). For these
purposes, patient experience is defined as something that
happened to a patient, or how something happened while
patient satisfaction refers to patients’ expectations and
whether they were met. As depicted in Table 2, questions
4 and 5 relate to patient experience, while the other
questions relate to patient satisfaction. The data were
analyzed as a whole and also grouped by five variables:
race, SCD severity, Hgb genotype, who completed the
questionnaire (parent/guardian versus patient), and
whether the ED visit resulted in hospital admission. An
ED visit that resulted in hospital admission was thought to
be severe enough to require inpatient management and
thus was used as a surrogate for the severity of an episode.
Two-tailed p-values less than 0.05 were considered
statistically significant.
To provide the context of the patient experience relevant
to this study, patients with SCD who present to the St.
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Table 3. Open-Ended and Yes/No Questions

8) My answers to one (or more) of the choices above
are different now than it would have been at the
beginning of the COVID-19 pandemic.
If Yes, Question number: __
My score would have been: ___
9) My biggest concern about going to the Emergency
Room was (circle all that apply):
(a) waiting area (b) registration
(c) other patients (d) providers (e) admissions
10) I was screened for COVID symptoms when I
arrived at the Emergency Room: Y / N
11) I used telemedicine (video or telephone
appointment) during the pandemic: Y / N
If Yes, how was the experience? ___

Christopher’s Hospital for Children ED are evaluated and
treated according to a standardized algorithm. For patients
with SCD and a fever greater than or equal to 38.5 degrees
Celsius, intravenous access is obtained, an appropriate
workup is initiated, and broad-spectrum intravenous
antibiotics are begun within one hour of arrival. For
patients with SCD and pain, patients are given intravenous
analgesics within 20 to 30 minutes of registration. The
treatment algorithms were not changed during the
COVID pandemic. However, new patient social distancing
and COVID-related safety measures were implemented
beginning in April 2020 and remain in place. All patients
and guardians are briefly interviewed upon arrival to the
ED to assess COVID-19 risk factors including pertinent
symptoms, recent travel, exposure to a suspected or
confirmed COVID-positive patient, and whether there is a
pending COVID-19 test. All patients and visitors to the
ED are screened for body temperature. All patients with
SCD who admitted from the ED to an inpatient bed
undergo a COVID-19 polymerase chain reaction (PCR)
test.

Results
Fifty-eight patients participated in the study. The overall
results for the first seven Likert-scale questions are
depicted in Table 4. Most patients reported that their
decision to go to the Emergency Room was affected by
the COVID-19 pandemic (n = 38; 62%). The responses to
question 1 were statistically significant across all groups
except for race. There were significant differences when
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patient responses were analyzed by hemoglobin genotype
(mean = 3.04 for Hgb SS versus a mean = 3.77 for other
genotypes, p = 0.047), whether the parent/guardian or
patient completed the questionnaire (mean = 2.72 for
parents/guardians, mean = 3.75 for patients, p = 0.01),
whether a patient was admitted (mean = 3.11 for admitted
patients versus a mean = 3.91 for those patients
discharged from the ED, p = 0.034), as well as disease
severity (mean = 2.83 for severe disease versus mean =
3.70 for disease considered as not severe, p = 0.03). These
results are illustrated in Figure 1.

disease symptoms were unchanged compared to before
the pandemic (n= 41; 70%) (Table 4).
All participants were asked if they would answer the
survey differently at the time that it was administered
compared to at the beginning of the pandemic (Table 3).
Five participants responded, and all felt differently about
their decision to go to the ED. Two participants were
more worried about returning to ED during the pandemic,
and three participants were more comfortable going to the
ED. Twenty-four participants responded to question 9
about their biggest concern for their ED visit. Most were
worried about other patients (n=18), followed by the
waiting area (n = 13), then ED providers (n = 2). All but 2
of the participants remembered being screened for
COVID-19 exposure and symptoms (n = 56; 97%). Most
participants did not choose to utilize telemedicine during
the pandemic (n = 39; 67%). Many participants
commented that the wait to see a provider in the ED was
not longer than usual, but the wait to get a hospital room
after admission was longer than usual, most likely due to
the time it took to obtain the results of COVID-19 PCR
testing.

Most participants responded that their experience in the
ED was the same during the pandemic as it was before the
pandemic (n = 45, 78%) (Table 4). The results were
statistically significant when analyzed by Hgb genotype
(mean = 3.37 for Hgb SS versus a mean = 3.06 for other
genotypes, p=0.046) (Figure 1). Most participants stated
that there was no change in the time it took to get an ED
bed or to receive medical care (n= 35; 60%) (Table 4). All
patients reported that they felt the ED personnel took
proper infectious precautions (n=58; 100%) (Table 4).
Overall, most participants felt their baseline sickle cell

Figure 1. Responses to Likert Questions 1 through 5, Analyzed by Subgroups
p=0.03
4.5

4

p=0.03

p=0.047

p=0.0

p=0.004
p=0.007 p=0.02

3.5

p=0.046

p=0.02

3
2.5

p=0.003

2
1.5
1
0.5
0
Q1

Admitted
Other Genotype
African American
Patient

Q2

Q3

Discharged from ED
Severe
Non- African American

Q4

Q5

Hgb SS
Not Severe
Parent

Subgroup analysis of response organized by question. 1) My decision to go to the Emergency Room was affected by
the COVID-19 pandemic. 2) I waited longer before going to the Emergency Room (vs. before pandemic). 3) I tried
more medications at home for fever and/or pain (vs. before the pandemic). 4) My experience in the Emergency Room
was better during the pandemic (vs. before the pandemic). 5) I got to a room in the ED and/or got care faster during
the pandemic (vs. before the pandemic).
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Table 4. Responses to Likert Questions
n (%)
Mean (SD)

Strongly Disagree

Disagree

Neutral

Agree

Strongly Agree

1

3.43 (1.41)

11 (19%)

3 (5%)

8 (14%)

22 (38%)

14 (24%)

2

2.52 (1.22)

18(31%)

8 (14%)

17 (29%)

14 (24%)

1(2%)

3

2.60 (1.25)

16 (28%)

9 (16%)

17 (30%)

12 (21%)

3 (5%)

4

3.21 (0.59)

0 (0%)

2 (3%)

45 (78%)

8 (14%)

3 (5%)

5

3.36 (0.77)

0 (0%)

4 (7%)

35 (60%)

13 (23%)

6 (10%)

6

5.00 (0)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

58 (100%)

7

3.03 (0.59)

0 (0%)

8 (14%)

41 (70%)

8 (14%)

1 (2%)

Question

1) My decision to go to the Emergency Room was affected by the COVID-19 pandemic.
2) I waited longer before going to the Emergency Room (vs. before pandemic).
3) I tried more medications at home for fever and/or pain (vs. before the pandemic).
4) My experience in the Emergency Room was better during the pandemic (vs. before the pandemic).
5) I got to a room in the ED and/or got care faster during the pandemic (vs. before the pandemic).
6) I felt the hospital took the proper infectious precautions (staff wore masks, ER was cleaned regularly, etc.).
7) I feel like my sickle cell disease symptoms (pain, fever, etc.) are milder now (vs. before the pandemic).

Discussion
Our results suggest that the COVID-19 pandemic has not
significantly affected patients’ experience in and
satisfaction with ED visits or their baseline SCD
symptoms. Overall, most people felt that the COVID-19
pandemic affected their decision to go to the Emergency
Room, which was also notable when analyzed by
subgroup. Patients with Hgb SS genotype, severe disease,
patients who were subsequently admitted to the hospital,
and parents responding to the survey were less affected by
the pandemic in their decision-making process. One
possible explanation is that patients who have the Hgb SS
genotype and severe disease are more likely to have more
serious and more frequent pain crises. Thus, their decision
to present to the ED was driven more by their relatively
worse symptoms, rather than such external factors as the
pandemic, compared to participants with other genotypes
and less severe disease. Using admission to the hospital as
a surrogate for episode severity, it can be argued that
patients who were having more severe episodes or crises
were less hesitant to go to the ED. Finally, when
considering who responded to the survey, recall bias and
parental concern may account for parents wishing to take
their children to the Emergency Room regardless of the
additional risks posed by the COVID-19 pandemic.
Interestingly, most participants did not wait longer than
usual before going to the ED and took the same amount
of medication for pain or fever as they usually did during
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the pandemic. Those patients with Hgb SS, severe disease,
and who self-identified as African American were less
likely to have waited before going to the ED. In addition,
those patients with Hgb SS and who self-identified as
African American were less likely to have taken more
medication before going to the ED as compared to before
the pandemic. These subgroups are more likely to have
more serious and frequent pain crises, which may account
for the observation that they did not delay in seeking
medical care. Given the evidence that patients with SCD
have a much higher risk of significant morbidity and
mortality if they were to contract SARS-CoV-2 than
patients without SCD, it is imperative that patients with
SCD do not defer seeking appropriate, emergent medical
attention.5
Although there is a substantial level of dissatisfaction with
ED care that has been well documented among the
population of patients with SCD, our results indicate that
the COVID-19 pandemic did not worsen patients’
experience or satisfaction with their care.7-8 Most of the
participants in this study reported that their experience in
the ED was similar to their ED experiences before the
pandemic, especially for those with the Hgb SS genotype.
All respondents reported that the hospital took
appropriate sanitary and social distancing precautions
implemented during the pandemic. This result is further
supported by most respondents not being concerned
about staying in the waiting room or by the ED providers,
but expressing concern about the potential risk posed by
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other patients. Our results infer that, as most patients did
not have a more negative experience in the ED during the
pandemic, they would not be opposed to returning to the
ED if necessary.
Overall, most participants felt their baseline sickle cell
disease symptoms were unchanged compared to before
the pandemic. One theory for the decrease in ED visits by
patients with SCD during the pandemic is that such
protective measures such as mask-wearing and social
distancing result in less spread of viral respiratory illnesses
in general, thereby leading to fewer SCD exacerbations.
Our data do not support this theory. Most participants
stated that there was no change in the time it took to get
an ED bed or to get medical care. Interestingly, most
participants did comment on the long wait time to get an
inpatient bed assigned, most likely due to the time it took
to run a COVID-19 PCR test per hospital protocol.
There are limitations to the study. The survey was
conducted with a relatively small sample size of patients
with SCD who were seen at a single pediatric ED.
Therefore, care should be taken when generalizing our
results. There is a risk of recall bias as the survey
questioned participants about a past ED visit. The study
was retrospective, as are most survey studies.
Despite the above limitations, this study is meaningful
given the consistently negative ED encounters historically
reported by patients with SCD. The results imply that the
COVID-19 pandemic did not deter those pediatric
patients with SCD who needed emergency care from
seeking it, and that their experience and satisfaction with
the ED was not substantially impacted by the additional
screening and safety protocols implemented during the
pandemic. To our knowledge, this is the first study of how
the COVID-19 pandemic has affected patients’ utilization
of, experience in, and satisfaction with a pediatric hospital
ED.
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